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Abstract
Background: African Americans have an increased incidence and worse prognosis with chronic kidney disease
(CKD - estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2) than their counterparts of European-
descent. Inflammation has been related to renal disease in non-Hispanic whites, but there are limited data on the
role of inflammation in renal dysfunction in African Americans in the community.
Methods: We examined the cross-sectional relation of log transformed C-reactive protein (CRP) to renal function
(eGFR by Modification of Diet and Renal Disease equation) in African American participants of the community-
based Jackson Heart Study’s first examination (2000 to 2004). We conducted multivariable linear regression relating
CRP to eGFR adjusting for age, sex, body mass index, systolic and diastolic blood pressure, diabetes, total/HDL
cholesterol, triglycerides, smoking, antihypertensive therapy, lipid lowering therapy, hormone replacement therapy,
and prevalent cardiovascular disease events. In a secondary analysis we assessed the association of CRP with
albuminuria (defined as albumin-to-creatinine ratio > 30 mg/g).
Results: Participants (n = 4320, 63.2% women) had a mean age ± SD of 54.0 ± 12.8 years. The prevalence of CKD was
5.2% (n = 228 cases). In multivariable regression, CRP concentrations were higher in those with CKD compared to those
without CKD (mean CRP 3.2 ± 1.1 mg/L vs. 2.4 ± 1.0 mg/L, respectively p < 0.0001). CRP was significantly associated
with albuminuria in sex and age adjusted model however not in the multivariable adjusted model (p > 0.05).
Conclusion: CRP was associated with CKD however not albuminuria in multivariable-adjusted analyses. The study
of inflammation in the progression of renal disease in African Americans merits further investigation.
Background
The incidence and mortality of chronic kidney disease
(CKD) is disproportionately higher in African Americans
compared to their white counterparts. In a 12-year fol-
low up cohort study of 9,082 African American and
white adults between 30-74 years of age, African Ameri-
cans’ risk of CKD was 2.7 times higher than that of
whites [1]. Although high rates of hypertension, diabetes
and obesity in the middle-aged African American popu-
lation contribute in part to the racial difference, the
disparities were not fully accounted for by risk factor
burden [1].
Recent data support the concept that C-reactive pro-
tein (CRP) is associated with the prevalence, progression
and prognosis of renal dysfunction in non-Hispanic
whites. Increasing CRP concentrations have been related
to both prevalent [2-5] and incident [6] CKD in this
group. Also a10-ml/minute/1.73 m2 lower estimate GFR
[(eGFR) among persons with eGFR <60 ml/minute/1.73
m2)] has been associated with an incidence rate ratio of
1.29 (95% confidence interval: 1.06, 1.55) for cardiovas-
cular mortality and a doubling of albuminuria has been
associated with an incidence rate ratio of 1.06 (95% con-
fidence interval: 1.04, 1.08) for cardiovascular mortality
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[7]. CRP concentrations association with albuminuria
may be affected by ethnicity and sex and this may part
of the clustering of cardiovascular risk factors and the
higher incidence of cardiovascular disease observed in
African Americans [8]. Despite the increased incidence
and poor sequelae from CKD, and the existing research
in non-Hispanic whites relating inflammation to CKD,
there are limited data on the relation of inflammatory
biomarkers to renal function and albuminuria in African
Americans. We hypothesized that renal function and
albuminuria are significantly related to systemic inflam-
mation in African Americans after adjusting for tradi-
tional cardiovascular risk factors.
Methods
Study Cohort and Design
The Jackson Heart Study is a longitudinal community-
based observational cohort that was initiated in 2000 to
prospectively investigate the epidemiology and determi-
nants of cardiovascular disease in African Americans
[9]. Thirty percent of study participants were former
members of the Jackson, Mississippi cohort of the
Atherosclerosis Risk in Communities study, and had
been recruited by random selection from the driver’s
license registry [10]. Among the remaining participants,
23% were recruited by random selection from the
“Accudata” list (a commercial listing that represents the
overall tri-county population). An additional 23% were
members of a constrained volunteer sample, in which
recruitment was distributed among defined demographic
cells in proportions designed to mirror those in the
overall tri-county population. Twenty-four percent of
participants were recruited through the Jackson Heart
Study Family Study, as described [11]. Among the 5,301
participants recruited for Examination 1, we studied
4320 participants after excluding participants for the fol-
lowing indications: missing CRP measurements (n =
105); those with self-reported malignancy, those using
medications suggesting underlying rheumatologic or
inflammatory disease, and those with a white blood cell
count > 12 suggesting infection (n = 312); missing cov-
ariates (n = 523); eGFR <15 ml/min/1.73 m2 (n = 20);
and missing eGFR (n = 21). The Jackson Heart Study
was approved by the University of Mississippi Medical
Center Institutional Review Board and participants gave
written informed consent.
Measurement of Renal Function
Biochemical testing for serum creatinine was performed
at the University of Mississippi Medical Center Labora-
tory Reading Center using a multi-point enzymatic spec-
trophotometric assay on a Vitros 950 Ortho-Clinical
Diagnostics analyzer. Creatinine values were biochemi-
cally calibrated to Cleveland Clinic-equivalent Minne-
sota Beckman CX3 assay for analysis purposes. Thus,
the primary measure of renal function was eGFR, as cal-
culated by the Modification of Diet and Renal Disease
(MDRD) equation [12]:
eGFR ml  m
P Age  iCR
( / min/ . )
( ) ( ) ( .. .
1 73
186 0 742
2
1 154 0 203

    f female  for African Americans) ( . ) 1 210
CKD was defined in the primary analysis as eGFR <60
ml/min/1.73 m2 [13,14]. In a secondary analysis, CRP
relation to albuminuria [defined as an urinary albumin-
to-creatinine ratio (UACR) of > 30 mg/g on spot or 24-
hour urine collection] was considered. A thorough dis-
cussion of the measurements for CKD and their relation
to interview and medical data in the Jackson Heart
Study has been previously published [15].
CRP measurement
We measured CRP using immunoturbidimetric CRP-
Latex assay from Kamiya Biomedical Company following
manufacturer’s high-sensitivity protocol. The inter-assay
coefficients of variation on control samples repeated in
each assay were 4.5% and 4.4% at CRP concentrations of
0.45 mg/L and 1.56 mg/L respectively. The reliability
coefficient for masked quality control replicates was 0.95
for the CRP assay.
Covariates
Body mass index (BMI) was calculated as the ratio of
fasting weight toheight squared (kg/m2). Obesity was
defined as a BMI ≥30 kg/m2. We defined hypertension
based on Joint National Commission VII guidelines
(≥140/90 mmHg, or reported use of antihypertensive
medications within two weeks prior to the visit) [16].
Our definition for diabetes was based on the American
Diabetes Association guidelines: participants were con-
sidered to have diabetes if they had one of the following:
fasting serum glucose ≥126 mg/dL or use of diabetic
medications within two weeks of the clinic visit, or his-
tory of physician-diagnosed diabetes [17]. Fasting serum
total to high density lipoprotein (HDL) cholesterol and
triglyceride concentrations were assessed with Roche
enzymatic methods using a Cobras centrifuge analyzer
(Hoffman-La Roche). Smoking status was defined as any
participant who had smoked at least 400 cigarettes in
their lifetime and was currently smoking at their base-
line examination. Prevalent cardiovascular disease was
defined as a stated history of physician-diagnosed myo-
cardial infarction or stroke, electrocardiographic evi-
dence of myocardial infarction, or history of a
revascularization procedure (percutaneous transluminal
coronary angioplasty or coronary artery bypass surgery).
Statistical Analysis
We performed descriptive statistics to determine the
mean, standard deviation (SD) and/or percentages for
study participants’ characteristics. Frequency distribu-
tions were used for categorical data. Descriptive statis-
tics were used to determine the characteristics of
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participants according to dichotomized CRP concentra-
tion (using the lower 75th percentile as cutoff). Descrip-
tive statistics were also used to determine characteristics
of Jackson Heart Study participants with and without
CKD.
Since its distribution was skewed, CRP concentration
was natural log-transformed for clinical correlates ana-
lyses [18]. By mean of general linear modeling (SAS
PROC GLM) age- and sex-adjusted linear regression
was used to assess the relation of CRP concentrations
(log transformed) to renal function (CKD). Multivariable
regression was used to assess the relation of CRP to
CKD accounting for cardiovascular disease risk factors
including age, sex, body mass index (BMI), systolic and
diastolic blood pressure, diabetes, total/HDL cholesterol,
triglycerides, smoking, antihypertensive therapy, lipid
lowering therapy, hormone replacement therapy, and
prevalent cardiovascular disease events. Effect modifica-
tion test of age, sex, obesity (BMI<30 versus ≥ 30 kg/m2),
prevalent CVD and prevalent MI were performed and
the analysis was stratified based on significant effect
modifiers at the significance level of 0.01.
In a secondary analysis, we investigated the relation of
CRP to albuminuria (UACR) by multivariable linear
regression adjusting the above mentioned covariates.
The presence or absence of albuminuria served as the
independent variable in the model. Analyses were con-
ducted with SAS version 9.2 (SAS Institute, Cary, NC).
A two-sided p-value < 0.01 was considered statistically
significant.
Results
Table 1 displays the clinical characteristics of the Jack-
son Heart Study by CRP (the lower 75th percentile and
upper 25th percentile) for the overall study population,
for those participants age < 60 years and for those parti-
cipants age ≥ 60 years. The prevalence of CKD based on
eGFR criteria alone was 5.2% (n = 226); mean eGFR
among individuals with CKD was 45.9 ± 13.7 ml/min/
1.73 m2. CKD was more prevalent in those participants
> 60 years old and the mean CRP concentration was
slightly higher in this group.
Table 2 shows the relation of CRP with CKD in the
study population. There was evidence of effect modifica-
tion by sex (p = 0.0061) therefore the analysis was strati-
fied. For both men and women, CRP concentrations
were higher in those with CKD compared to those with-
out CKD. Between the CKD and non-CKD groups,
Table 1 Characteristics of Study Participants in the Lower 75th and Upper 25th percentile of C-Reactive Protein
Stratified by Age 60 years
Overall Age < 60 years Age ≥ 60 years
L75thP CRP
(< 5.7 mg/L)
n = 3254
U25thP CRP
(≥ 5.7 mg/L)
n = 1066
L75thP CRP
(< 5.7 mg/L)
n = 2071
U25thP CRP
(≥ 5.7 mg/L)
n = 663
L75thP CRP
(< 5.7 mg/L)
n = 1183
U25thP CRP
(≥ 5.7 mg/L)
n = 403
C-reactive protein mg/L 2.1 ± 1.5 14.4 ± 15.2 2.0 ± 1.5 14.1 ± 10.6 2.2 ± 1.5 14.9 ± 20.6
Demographic factors
Age, years 54 ± 13 54 ± 12 46 ± 9 47 ± 8 67 ± 6 67 ± 6
Male, % 42.01 18.57 45.3 18.4 36.3 18.9
Cardiovascular risk factors
Body mass index, kg/m2 30.3 ± 6.1 36.1 ± 8.3 30.4 ± 6.3 37.4 ± 8.3 30.1 ± 5.8 34.0 ± 7.8
Systolic blood pressure, mmHg 127 ± 18 127 ± 18 123 ± 16 124 ± 16 134 ± 20 133 ± 20
Diastolic blood pressure, mmHg 80 ± 10 78 ± 10 81 ± 10 80 ± 10 78 ± 10 75 ± 11
Hypertension, % 57.6 69.0 46.3 57.6 77.4 87.6
Diabetes, % 13.7 18.9 9.8 15.5 20.6 24.3
Total/HDL cholesterol, ratio 4.1 ± 1.3 4.1 ± 1.4 4.2 ± 1.4 4.1 ± 1.5 4.0 ± 1.2 4.1 ± 1.3
Triglyceride, mg/dL 104 ± 76 113 ± 80 102 ± 83 109 ± 69 107 ± 63 119 ± 95
Current smoker, % 12.2 14.4 14.3 15.9 8.7 12.0
Anti-hypertension therapy, % 46.8 60.1 34.3 48.9 68.6 78.5
Lipid lowering therapy, % 12.0 10.5 6.8 7.8 21.1 14.9
HRT use in women, % 11.2 24.1 10.6 22.9 12.1 26.0
Nutritional factors
Total protein 79 ± 47 77 ± 48 86 ± 51 86 ± 53 66 ± 35 64 ± 35
Kidney disease factors
Chronic kidney disease, % 4.2 8.4 1.5 4.2 8.9 15.4
Values are % or mean ± standard deviation
HRT, hormone replacement therapy, L75th = lower 75th percentile, U25 = upper 25th percentile
Chronic kidney disease is defined as a glomerular filtraction rate, 60 ml/min/1.73 m2
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there were greater differences in CRP in men compared
to women. Therefore, the changes were in the same
direction for both sexes, and the type of effect modifica-
tion by sex was synergist. There was no effect modifica-
tion by age, obesity, prevalent CVD or prevalent MI.
Age-adjusted CRP concentration was significantly asso-
ciated with CKD for both women (p = 0.02) and men
(< 0.0001). After adjusting for age, BMI, systolic and
diastolic blood pressure, diabetes, total/HDL cholesterol,
triglycerides, smoking, lipid lowering therapy, hormone
replacement therapy in women, and prevalent CVD
events in the multivariable regression, CRP remained
strongly associated with CKD for both women and men
(p < 0.0001 for both). (See Additional file 1 for results
of additional sub-analysis).
Secondary analyses
In a secondary analysis we assessed the relation of CRP
with albuminuria (based on spot or 24-hour urine values
with an UACR > 30 mg/g). (Table 3) The prevalence of
albuminuria was 10.8% (n = 298) among the 2,750 parti-
cipants with urine to calculate UACR. CRP was signifi-
cantly associated with albuminuria in the age and sex
adjusted model (< 0.0001) but was not in the multivari-
able-adjusted model (p = 0.16). There was no evidence
Table 2 Association of C-Reactive Protein with Chronic Kidney Disease (ml/min/1.73 m2) in the Pooled Study
Population and Stratified by Sex
CKD (eGFR < 60) No CKD (eGFR ≥ 60) p-value
Pooled**
N 228 4092
CRP (Geometric Mean ± SE) CRP (Geometric Mean ± SE)
Adjustment
Age and Sex 3.4 ± 1.1 mg/L 2.4 ± 1.0 mg/L < 0.0001
Multivariable* 3.2 ± 1.1 mg/L 2.4 ± 1.0 mg/L < 0.0001
Women
N 178 2577
CRP (Geometric Mean ± SE) CRP (Geometric Mean ± SE)
Adjustment
Age 3.9 ± 1.1 mg/L 3.0 ± 1.0 mg/L 0.016
Multivariable*† 3.7 ± 1.1 mg/L 3.1 ± 1.0 mg/L < 0.0001
Men
N 50 1515
CRP (Geometric Mean ± SE) CRP (Geometric Mean ± SE)
Adjustment
Age 3.4 ± 1.2 mg/L 1.58 ± 1.0 mg/L < 0.0001
Multivariable*† 3.1 ± 1.2 mg/L 1.58 ± 1.0 mg/L < 0.0001
* adjusted for age, sex, body mass index, systolic and diastolic blood pressures, diabetes, current smoking status, hypertension drugs, lipid lowering drugs,
hormone therapy replacement, triglycerides, total cholesterol/HDL ratio, and prevalent cardiovascular disease events.
** pooled signify both men and women included in the analysis
† sex is excluded from list of covariates since analysis is stratified by sex
CKD, Chronic kidney disease; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein
Table 3 Association of C-Reactive Protein with Albuminuria (UACR > 30 mg/g)
Albuminuria Present Albuminuria Absent p-value
Pooled**
N 298 2452
CRP (Geometric Mean ± SE) CRP (Geometric Mean ± SE)
Adjustment
Age and Sex 2.2 ± 1.0 mg/L 3.0 ± 1.1 mg/L < 0.0001
Multivariable* 2.3 ± 1.0 mg/L 2.5 ± 1.1 mg/L 0.16
* adjusted for age, sex, body mass index, systolic and diastolic blood pressures, diabetes,
current smoking status, hypertension drugs, lipid lowering drugs, hormone therapy replacement,
triglycerides, total cholesterol/HDL ratio, and prevalent cardiovascular disease events.
** pooled signify both men and women included in the analysis
UACR = urinary albumin-to-creatinine ratio; CRP, C-reactive protein
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of effect modification by age, sex, obesity, prevalent
CVD or prevalent MI on the relation of CRP with
albuminuria.
Discussion
Principal Findings
We found a significant association between higher mean
CRP concentrations and CKD for women and men after
adjusting for multiple traditional cardiovascular risk fac-
tors. In the secondary analysis, we found that CRP was
significantly associated with albuminuria in age- and
sex- adjusted models. CRP was not significantly asso-
ciated with albuminuria in the multivariable adjusted
model. This finding speaks against a glomerular
involvement.
We found that the prevalence of CKD using eGFR by
MDRD formula was 5.2% in this cohort. This result is
somewhat surprising given the prevalence of stage III
CKD was estimated at 7.7% in the recent analysis by
Coresh et.al in the NHANES 1999-2004 population
(a nationally representative sample of non-institutiona-
lized adults aged 20 years or older) [15,19]. This may be
affected by a number of factors including that hyperten-
sion control in our cohort was greater than that of the
AA in NHANES and that differences in sample recruit-
ment between our cohort and that in NHANES may
favor a lower percentage of unhealthy individuals and
subsequently lower prevalence of CKD in the Jackson
Heart Study.
Relation of CRP to CKD: Comparison with Prior Literature
Our finding of a significant association between CRP (as
a marker of systemic inflammation) and CKD in the
African American population-based cohort of the Jack-
son Heart Study is similar to that seen in the Nether-
lands Study (a large population-based cohort consisting
of 7,317 non-Hispanic white individuals without dia-
betes). In a cross-sectional analysis of the cohort, CRP
was significantly associated with lower GFR in the mul-
tivariable model (OR 1.9;95% CI 1.3 to 2.9) [5]. Two
recent smaller studies in individuals with diabetes
showed a relation between inflammatory markers and
CKD, though in neither study was there a significant
association with CRP[20,21] In the Cardiovascular
Health Study, a community-based cohort of elderly indi-
viduals, CRP and other markers of systemic inflamma-
tion remained associated with a rise in creatinine after
adjusting for multiple clinical risk factors including race
(follow up period of nine years for the original cohort
and four years for the more recently recruited African
American cohort). Similar results were found for decline
in estimated GFR. The decline in eGFR was greater with
increasing number of inflammatory or prothrombotic
markers that were above the median [22].
In addition to its relation to the progression of renal
disease, CRP has been a strong predictor of cardiovascu-
lar events in those with reduced renal function [12,23].
For example, in an 8-year follow-up of women in the
Nurses’ Health Study, the odds ratio per 5 mg/L
increase in CRP was 1.68 (95% CI, 1.13 to 2.52) for
women with an estimated creatinine clearance of ≤ 74
ml/min compared with 1.23 (95% CI, 0.86 to 1.76) and
0.99 (95% CI, 0.76 to 1.29) for women with an estimated
creatinine clearance of 75 to 89 and ≥ 90 ml/min,
respectively. Those with end-stage renal disease but not
on dialysis and those with mild renal insufficiency are at
increased risk for the development of cardiovascular dis-
ease, which cannot be attributed entirely to traditional
risk factors of diabetes, hypertension and obesity [24,25].
Our results suggest that inflammation relates to CKD
and may represent an additional (non-traditional) risk
factor for cardiovascular events in those with CKD.
Mechanism linking CRP with renal function
A number of theories have been advanced to explain the
link between the deterioration of renal function and
inflammation. One theory is that renal dysfunction is
related to inflammation through the reduction in the
nitric oxide synthase activity [26]. Nitric oxide synthase
is linked to inflammation through its role in the forma-
tion of peroxynitrate, an important mediator of the
immune response. One proposed explanation for higher
CRP concentrations with CKD is that there is dimin-
ished filtration of CRP in end-stage renal disease [24].
However, it has been established that CRP is filtered in
negligible amounts in the glomerulus and reabsorbed by
the distal renal tubules. Therefore, elevation of CRP in
CKD is not satisfactorily answered by this theory
[24,27].
Yet another theory suggests that CKD and CRP are
related through shared risk factors. It is known that
hypertension, obesity and diabetes are all strongly
related to both systemic inflammation and renal dys-
function [5]. Inflammation may be associated with
hypertension and the development and progression of
renal dysfunction through activation of the renin-angio-
tensin system and its influence on endothelial function
[28-31]. Similarly inflammation is related to obesity
through the production of cytokines by adipocytes
[32,33] and may therefore be related to renal dysfunc-
tion through this relation with obesity. It is known that
obesity is associated with end-stage renal disease
through its strong correlation with type 2 diabetes and
hypertension [5].
Finally, others have shown that higher CRP concentra-
tions are related to reduced kidney cortex width and
reduced renal cortex width is related to increased blood
pressure [34,35] Hence, CRP may be a marker of kidney
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inflammation with increased scarring in the kidney cor-
tex, which may then relate to blood pressure.
Strengths and Limitations
There are a number of limitations of our study. First,
the study population consists solely of African Ameri-
cans and so the generalizability of this study to other
ethnic groups is unclear. Second, this study is cross-sec-
tional and therefore cause-effect relations cannot be
determined. Third, because data are derived from the
first visit for the Jackson Heart Study cohort, investiga-
tors were unable to assess the effects of longitudinal
exposure to environmental factors. Fourth, renal func-
tion in the current analysis was estimated using the
MDRD eGFR formula (a recommended means of esti-
mating kidney function). MDRD has stronger specificity
than sensitivity in predicting kidney problems. The
more direct measure of kidney disease (using iothala-
mate or iohexol clearance to measure GFR) is not feasi-
ble in a population-based setting. Balanced against these
caveats, the strength of this study lies in the prospective
collection of CRP concentrations and covariates in a
large population-based cohort of African Americans.
Conclusion
Our study found that CRP is significantly related to CKD
as defined by eGFR < 60 ml/min/1.73 m2 in African
Americans. Given the disproportionate burden of renal
dysfunction in the African American community, future
investigations should focus on the relation of CRP to the
development and progression of renal disease and
whether lower CRP in longitudinal studies predict
improvement in renal function over time. Such findings
would suggest that CRP as a marker of systemic inflam-
mation may serve as a potential target for treatment and
prevention. Research into genetic factors contributing to
CRP variation in African Americans may also provide
further understanding of how systemic inflammation
relates to renal dysfunction in this group [36].
Additional file 1: Summary Results of Additional Sub-analysis.
Additional sub-analysis was performed examining the association
between CRP (log transformed) and CKD status by means of linear
regression models. Two set of linear regression models were derived, the
first was age and sex-adjusted and the second was multivariable
adjusted. CKD status was categorized into normal (eGFR ≥ 90 and
absence of albuminuria) and CKD Stages 1 (eGFR ≥ 90 and presence of
albuminuria), 2 (60 ≤ eGFR ≤ 89 and presence of albuminuria), and 3 (30
≤ eGFR ≤ 59). P trend was computed to assess the linear trend in the
levels of CRP as one progress from normal to Stage 3 of CKD. Results of
the analysis are summarized below (see Table S2a). The geometric means
( ± standard error) and confidence intervals for the various categories of
CKD status are provided in a Table S2a. entitled “Association of C-
Reactive Protein with Chronic Kidney Disease (ml/min/1.73 m2)”.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2369-11-1-
S1.DOC ]
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